Objective:

To examine the relationship between metabolic syndrome (MetS) components and the development of malignant neoplasms of the brain (MNBs) and to identify the most significant influence.

Approach:

Key Findings:

• Individual component counts did not reach statistical significance against the zero-component reference.
• Participants with ≥3 MetS components showed a statistically significant increased MNB risk (HR: 1.091).
• Elevated triglycerides had the strongest independent association with MNB risk (adjusted HR: 1.517).

Interpretation:

The cumulative burden of MetS was modestly associated with MNB risk, particularly through elevated triglycerides, but no mechanistic inference can be drawn.

Limitations:

• The outcome variable encompasses a diagnostically heterogeneous group of brain malignancies identified by administrative ICD-10 coding.
• No mechanistic inference or histological subtype-specific conclusion can be drawn from the data.
• Findings should be considered hypothesis-generating and require prospective validation.

Conclusion:

The study suggests that metabolic health management, particularly lipid monitoring, may inform brain tumor risk assessment.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.